Nimodipine
- Generic Name
- Nimodipine
- Brand Names
- Nimotop, Nymalize
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26N2O7
- CAS Number
- 66085-59-4
- Unique Ingredient Identifier
- 57WA9QZ5WH
- Background
Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compare...
- Indication
For use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits.
- Associated Conditions
- Delayed Ischemic Neurological Deficit
- Associated Therapies
- -
Glutaminergic Agents for Cocaine Abuse - 5
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Yale University
- Registration Number
- NCT00000280
- Locations
- 🇺🇸
VA Connecticut Healthcare System, New Haven, Connecticut, United States
High Dose Nimodipine Treatment Adjunct - 1
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Registration Number
- NCT00000332
- Locations
- 🇺🇸
Washington DC VA, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.